Koji Kawakami

Summary

Affiliation: University of Tokyo
Country: Japan

Publications

  1. ncbi IL-13 receptor-targeted cytotoxin cancer therapy leads to complete eradication of tumors with the aid of phagocytic cells in nude mice model of human cancer
    Koji Kawakami
    Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    J Immunol 169:7119-26. 2002
  2. ncbi Specifically targeted killing of interleukin-13 (IL-13) receptor-expressing breast cancer by IL-13 fusion cytotoxin in animal model of human disease
    Koji Kawakami
    Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD, USA
    Mol Cancer Ther 3:137-47. 2004
  3. ncbi Nitric oxide accelerates interleukin-13 cytotoxin-mediated regression in head and neck cancer animal model
    Koji Kawakami
    Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Clin Cancer Res 10:5264-70. 2004
  4. ncbi Hodgkin lymphoma therapy with interleukin-4 receptor-directed cytotoxin in an infiltrating animal model
    Mariko Kawakami
    Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapeutics, Center for Biologics Evaluation and Research, Food and Drug Administration, NIH Bldg 29B 2E08, Bethesda, MD 20892, USA
    Blood 105:3707-13. 2005
  5. ncbi Targeted anticancer immunotoxins and cytotoxic agents with direct killing moieties
    Koji Kawakami
    Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Yoshida Konoecho, Sakyoku, Kyoto 606 8501, Japan
    ScientificWorldJournal 6:781-90. 2006
  6. ncbi Characterization of a novel human tumor antigen interleukin-13 receptor alpha2 chain
    Koji Kawakami
    Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA
    Cancer Res 66:4434-42. 2006
  7. ncbi Intratumoral therapy with IL13-PE38 results in effective CTL-mediated suppression of IL-13Ralpha2-expressing contralateral tumors
    Koji Kawakami
    Tumor Vaccines and Biotechnology Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville Pike, Rockville, Maryland, USA
    Clin Cancer Res 12:4678-86. 2006
  8. ncbi Cancer gene therapy utilizing interleukin-13 receptor alpha2 chain
    Koji Kawakami
    Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD, USA
    Curr Gene Ther 5:213-23. 2005
  9. ncbi Tumor regression mechanisms by IL-13 receptor-targeted cancer therapy involve apoptotic pathways
    Mariko Kawakami
    Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Int J Cancer 103:45-52. 2003
  10. ncbi Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-targeted cytotoxin composed of IL-13 antagonist and Pseudomonas exotoxin
    Mitomu Kioi
    Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Clin Cancer Res 10:6231-8. 2004

Collaborators

Detail Information

Publications65

  1. ncbi IL-13 receptor-targeted cytotoxin cancer therapy leads to complete eradication of tumors with the aid of phagocytic cells in nude mice model of human cancer
    Koji Kawakami
    Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    J Immunol 169:7119-26. 2002
    ....
  2. ncbi Specifically targeted killing of interleukin-13 (IL-13) receptor-expressing breast cancer by IL-13 fusion cytotoxin in animal model of human disease
    Koji Kawakami
    Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD, USA
    Mol Cancer Ther 3:137-47. 2004
    ..Taken together, local gene transfer of IL-13Ralpha2 followed by receptor-targeted IL-13 cytotoxin therapy may be applied safely and effectively to the treatment of localized breast cancer...
  3. ncbi Nitric oxide accelerates interleukin-13 cytotoxin-mediated regression in head and neck cancer animal model
    Koji Kawakami
    Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Clin Cancer Res 10:5264-70. 2004
    ....
  4. ncbi Hodgkin lymphoma therapy with interleukin-4 receptor-directed cytotoxin in an infiltrating animal model
    Mariko Kawakami
    Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapeutics, Center for Biologics Evaluation and Research, Food and Drug Administration, NIH Bldg 29B 2E08, Bethesda, MD 20892, USA
    Blood 105:3707-13. 2005
    ..Because numerous H-RS cell lines express receptors for IL-4, IL-4 cytotoxin may be a unique agent for the treatment of Hodgkin lymphoma...
  5. ncbi Targeted anticancer immunotoxins and cytotoxic agents with direct killing moieties
    Koji Kawakami
    Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Yoshida Konoecho, Sakyoku, Kyoto 606 8501, Japan
    ScientificWorldJournal 6:781-90. 2006
    ..This review summarizes the generation, mechanism, and development of these agents. In addition, possible future directions of this therapeutic approach are discussed...
  6. ncbi Characterization of a novel human tumor antigen interleukin-13 receptor alpha2 chain
    Koji Kawakami
    Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA
    Cancer Res 66:4434-42. 2006
    ..Taken together, our results identify the human IL-13Ralpha2 chain as a novel tumor rejection antigen...
  7. ncbi Intratumoral therapy with IL13-PE38 results in effective CTL-mediated suppression of IL-13Ralpha2-expressing contralateral tumors
    Koji Kawakami
    Tumor Vaccines and Biotechnology Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville Pike, Rockville, Maryland, USA
    Clin Cancer Res 12:4678-86. 2006
    ....
  8. ncbi Cancer gene therapy utilizing interleukin-13 receptor alpha2 chain
    Koji Kawakami
    Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD, USA
    Curr Gene Ther 5:213-23. 2005
    ..In addition, safety issues and possible future directions utilizing this therapeutic approach are discussed...
  9. ncbi Tumor regression mechanisms by IL-13 receptor-targeted cancer therapy involve apoptotic pathways
    Mariko Kawakami
    Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Int J Cancer 103:45-52. 2003
    ..In addition, apoptotic molecules may serve as surrogate molecular markers of tumor response to IL-13R-directed cytotoxin therapy...
  10. ncbi Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-targeted cytotoxin composed of IL-13 antagonist and Pseudomonas exotoxin
    Mitomu Kioi
    Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Clin Cancer Res 10:6231-8. 2004
    ..These results indicate that in general, IL13E13K-PE38 mediates similar cytotoxicity and antitumor activity to wtIL13-PE38 despite its improved binding affinity to IL-13 receptors...
  11. ncbi Intratumor administration of interleukin 13 receptor-targeted cytotoxin induces apoptotic cell death in human malignant glioma tumor xenografts
    Mariko Kawakami
    Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, NIH Building 29B, Room 2NN10, 29 Lincoln Drive MSC4555, Bethesda, MD 20892, USA
    Mol Cancer Ther 1:999-1007. 2002
    ..Our studies will help unravel the molecular pathways of cell death associated with tumor regression and provide additional insight and define apoptosis as possible surrogate marker of tumor response...
  12. ncbi Use of telomelysin (OBP-301) in mouse xenografts of human head and neck cancer
    Oumi Nakajima
    Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto 606 8501, Japan
    Oncol Rep 22:1039-43. 2009
    ..A regimen of three weekly injections of OBP-301 has remarkable antitumor effects against large KCCT873 tumors. These results may provide a new platform for treating patients with localized SCCHN...
  13. ncbi Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin
    Bharat H Joshi
    Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Clin Cancer Res 8:1948-56. 2002
    ..Thus, IL-13 cytotoxin may be a useful agent for high IL-13R-expressing SCCHN...
  14. ncbi Interleukin-4 receptor-targeted cytotoxin therapy of androgen-dependent and -independent prostate carcinoma in xenograft models
    Syed R Husain
    Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Mol Cancer Ther 2:245-54. 2003
    ..IL4-CTx appeared to be well tolerated. On the basis of these results, combining i.t. injections of IL4-CTx with systemic administration may provide an effective strategy for treating patients with advanced, refractory prostate cancer...
  15. ncbi Targeting interleukin-4 receptor α with hybrid peptide for effective cancer therapy
    Liying Yang
    Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Yoshidakonoe cho, Sakyo ku, Kyoto, Japan
    Mol Cancer Ther 11:235-43. 2012
    ..These results indicate that the IL-4Rα-lytic peptide generated in this study has a potent and selective anticancer potential against IL-4Rα-positive solid cancers...
  16. ncbi IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis
    Stefan Fichtner-Feigl
    Mucosal Immunity Section, Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 10 CRC 5W3864, 10 Center Drive, Bethesda, Maryland 20892, USA
    Nat Med 12:99-106. 2006
    ..These data suggest that IL-13Ralpha(2) signaling during prolonged inflammation is an important therapeutic target for the prevention of TGF-beta(1)-mediated fibrosis...
  17. ncbi Expression and targeting of interleukin-4 receptor for primary and advanced ovarian cancer therapy
    Mitomu Kioi
    Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Cancer Res 65:8388-96. 2005
    ..These results indicate that IL-4R-targeted cytotoxin may be a useful agent for the management of patients with ovarian cancer, and further studies need to be done to evaluate its safety, tolerability, and efficacy...
  18. ncbi Effect of interleukin (IL)-4 cytotoxin on breast tumor growth after in vivo gene transfer of IL-4 receptor alpha chain
    Koji Kawakami
    Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Clin Cancer Res 9:1826-36. 2003
    ..This study provides proof of principle that i.t. IL-4Ralpha plasmid injection followed by systemic or i.t. IL-4 cytotoxin administration may be a useful strategy for the treatment of breast cancer...
  19. ncbi Interleukin 4 receptor on human lung cancer: a molecular target for cytotoxin therapy
    Mariko Kawakami
    Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Clin Cancer Res 8:3503-11. 2002
    ..Because IL-4 cytotoxin mediates its antitumor activity through IL-4R, and a variety of lung tumors expressed high levels of IL-4R, we propose testing the safety of this agent in patients with lung cancer...
  20. ncbi Improved anti-tumor activity and safety of interleukin-13 receptor targeted cytotoxin by systemic continuous administration in head and neck cancer xenograft model
    Koji Kawakami
    Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Mol Med 8:487-94. 2002
    ..CONCLUSION: With a CI schedule, IL-13 cytotoxin can be systemically administrated at approximately twice the dose otherwise given by daily IV bolus administration...
  21. ncbi Antitumor therapy with bacterial DNA and toxin: complete regression of established tumor induced by liposomal CpG oligodeoxynucleotides plus interleukin-13 cytotoxin
    Ken J Ishii
    Division of Viral Products, Center for Biologics Evaluation Research, United States Food and Drug Administration, Bethesda, Maryland 20892, USA
    Clin Cancer Res 9:6516-22. 2003
    ..These data strongly suggest that a combination of innate immune activation by (CpG ODN)(SSCL) and tumor-directed targeting by IL13-PE is a novel approach for human cancer immunotherapy...
  22. ncbi Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model
    Koji Kawakami
    Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    J Neurosurg 101:1004-11. 2004
    ..These findings are highly relevant and important for the optimal clinical development of IL-13 cytotoxin or any other targeted antitumor agent for GBM therapy, in which multiple routes of delivery of an agent are being contemplated...
  23. ncbi TGF-beta receptor I conditional knockout mice develop spontaneous squamous cell carcinoma
    Yasuyuki Honjo
    Functional Genomics Section, Laboratory of Cellular and Developmental Biology, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland 20892, USA
    Cell Cycle 6:1360-6. 2007
    ..This is the first demonstration that loss of TbetaRI can lead to spontaneous tumor formation. These mice can serve as a unique mouse model of SCC to evaluate the tumorigenicity and effect of anti-cancer therapeutics...
  24. ncbi Evidence that IL-13R alpha2 chain in human glioma cells is responsible for the antitumor activity mediated by receptor-directed cytotoxin therapy
    Koji Kawakami
    Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    J Immunother (1997) 28:193-202. 2005
    ..These results indicate that IL-13R alpha2 chain in GBM cells is essential for IL-13 cytotoxin-induced cytotoxicity and that IL-13R alpha2 chain plays a critical biologic role in IL-13 cytotoxin-mediated therapy for GBM...
  25. ncbi Combined effects of radiation and interleukin-13 receptor-targeted cytotoxin on glioblastoma cell lines
    Koji Kawakami
    Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Int J Radiat Oncol Biol Phys 63:230-7. 2005
    ..CONCLUSIONS: Our results suggest that concomitant radiation therapy and IL13-PE38 treatment may be beneficial for the treatment of patients with GBM. This strategy may be worth exploring in animal models of human glioma...
  26. ncbi A novel transferrin receptor-targeted hybrid peptide disintegrates cancer cell membrane to induce rapid killing of cancer cells
    Megumi Kawamoto
    Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan
    BMC Cancer 11:359. 2011
    ..In this study, we designed TfR binding peptide connected with this novel lytic peptide and assessed the cytotoxic activity in vitro and in vivo...
  27. ncbi Semaphorin 3A lytic hybrid peptide binding to neuropilin-1 as a novel anti-cancer agent in pancreatic cancer
    Hanae Ueyama
    Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Yoshidakonoe cho, Sakyo ku, Kyoto 606 8501, Japan
    Biochem Biophys Res Commun 414:60-6. 2011
    ..These results indicate that Sema3A-lytic hybrid peptide would be a possible anti-cancer agent for treatment of human pancreatic cancer...
  28. ncbi Mechanism of action of interleukin-13 antagonist (IL-13E13K) in cells expressing various types of IL-4R
    Mitomu Kioi
    Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Cell Immunol 229:41-51. 2004
    ..Thus, IL-13E13K may be a useful agent for the treatment of diseases such as asthma, allergic rhinitis, and cancer, which are dependent on signaling through both IL-4 and IL-13 receptors...
  29. ncbi Targeting interleukin-4 receptors for effective pancreatic cancer therapy
    Koji Kawakami
    Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Cancer Res 62:3575-80. 2002
    ..Thus, IL-4 receptor-targeted cytotoxin represents a potent agent that may provide an effective therapy for pancreatic cancer...
  30. ncbi A novel hybrid peptide targeting EGFR-expressing cancers
    Masayuki Kohno
    Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan
    Eur J Cancer 47:773-83. 2011
    ..Thus, hybrid peptide can be a unique and powerful tool for a new cancer-targeted therapy...
  31. ncbi Analysis of interleukin-13 receptor alpha2 expression in human pediatric brain tumors
    Mariko Kawakami
    Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Cancer 101:1036-42. 2004
    ..Because the IL-13Ralpha2 chain is a major binding component of the IL-13R complex, these results suggest that the targeting of IL-13R may represent a useful approach for the treatment of pediatric brain tumors...
  32. ncbi A single replacement of histidine to arginine in EGFR-lytic hybrid peptide demonstrates the improved anticancer activity
    Noriko Tada
    Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Yoshidakonoe cho, Sakyo ku, Kyoto 606 8501, Japan
    Biochem Biophys Res Commun 407:383-8. 2011
    ..These results suggest that mutated arginine on EGFR-lytic peptide produces higher binding ability to EGFR on cancer cells, and thereby the improved anticancer activity...
  33. ncbi Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy
    Mariko Kawakami
    Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    J Neurooncol 65:15-25. 2003
    ..The central nervous system toxicities observed were attributed to the volume of infusion and/or nonspecific toxicity. Ongoing clinical trials will reveal antitumor activities of IL-4 cytotoxin in recurrent malignant glioma...
  34. ncbi Internalization property of interleukin-4 receptor alpha chain increases cytotoxic effect of interleukin-4 receptor-targeted cytotoxin in cancer cells
    Koji Kawakami
    Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Clin Cancer Res 8:258-66. 2002
    ..Taken together, a combination approach that involves transfer of the IL-4Ralpha gene and IL-4R-targeted cytotoxin therapy may serve as a novel approach for cancer therapy...
  35. ncbi Designed hybrid TPR peptide targeting Hsp90 as a novel anticancer agent
    Tomohisa Horibe
    Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Yoshida Konoecho, Sakyo ku, Kyoto, 606 8501, Japan
    J Transl Med 9:8. 2011
    ..Since Hsp90 is typically involved in cell proliferation and survival, this is thought to play a key role in cancer, and Hsp90 has attracted considerable interest in recent years as a potential therapeutic target...
  36. ncbi Characterization of antilytic peptide antibody: application for the detection of lytic-based hybrid peptide in serum samples
    Koji Ohara
    Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Yoshida Konoecho, Sakyoku, Kyoto 606 8501, Japan
    J Pept Sci 17:493-8. 2011
    ..v. administration of EGFR-lytic peptide to mice. These results indicate that this antibody will be a useful tool for the detection of lytic-based peptides to investigate their in vivo stability and pharmacokinetics...
  37. ncbi Antedrug budesonide by intrapulmonary treatment attenuates bleomycin-induced lung injury in rats with minimal systemic adverse effects
    Masayuki Kohno
    Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan
    Biol Pharm Bull 33:1206-11. 2010
    ..6-fold higher than the AUC of DEX in the lung. This study suggests that antedrug BUD by intrapulmonary treatment has local anti-inflammatory and antifibrotic effects with minimal systemic adverse effects...
  38. ncbi Direct association of thioredoxin-1 (TRX) with macrophage migration inhibitory factor (MIF): regulatory role of TRX on MIF internalization and signaling
    Aoi Son
    Department of Biological Responses, Institute for Virus Research, Kyoto University, Kyoto 606 8507, Japan
    Antioxid Redox Signal 11:2595-605. 2009
    ..7 cells. These results suggest that the cell surface TRX serves as one of the MIF binding molecules or MIF receptor component and inhibits MIF-mediated inflammatory signals...
  39. ncbi Interleukin-13 receptor alpha2 chain in human head and neck cancer serves as a unique diagnostic marker
    Mariko Kawakami
    Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Clin Cancer Res 9:6381-8. 2003
    ..Taken together, this study suggests that IL-13R may be involved in SCCHN tumor progression, and 33% of IL-13Ralpha2-positive SCCHN cases may be targeted by IL-13 cytotoxin and IL-13R-targeted agent...
  40. ncbi Apoptotic pathways of cell death induced by an interleukin-13 receptor-targeted recombinant cytotoxin in head and neck cancer cells
    Mariko Kawakami
    Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, NIH Building 29B, Room 2NN10, 29 Lincoln Drive MSC 4555, Bethesda, MD 20892, USA
    Cancer Immunol Immunother 50:691-700. 2002
    ..This information may be useful in developing specific approaches where apoptotic bodies from tumor cells may be used to pulse antigen-presenting cells for immunotherapy of cancer...
  41. ncbi Telomerase-specific virotherapy in an animal model of human head and neck cancer
    Oumi Nakajima
    Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Yoshida Konoecho, Sakyo ku, Kyoto 606 8501, Japan
    Mol Cancer Ther 8:171-7. 2009
    ..In addition, no significant toxicity was observed in animals receiving treatment. These results suggest that OBP-301 is a novel therapeutic agent with promise for the treatment of human head and neck cancers...
  42. ncbi Pancreatic cancer therapy with a novel pump for controlled drug release
    Mari Haramoto
    Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Sakyoku, Kyoto, Japan
    Oncol Rep 23:365-70. 2010
    ....
  43. ncbi Chromosomal variability of human mesenchymal stem cells cultured under hypoxic conditions
    Hanae Ueyama
    Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Yoshidakonoecho, Sakyo ku, Kyoto, Japan
    J Cell Mol Med 16:72-82. 2012
    ..In conclusion, we propose that the continuous monitoring of hMSCs will be required before they are used in therapeutic applications in the clinic, especially when cells are cultured under hypoxic conditions...
  44. ncbi Protein disulfide isomerase-immunopositive inclusions in patients with amyotrophic lateral sclerosis
    Yasuyuki Honjo
    Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Japan
    Amyotroph Lateral Scler 12:444-50. 2011
    ..In conclusion, we assume that PDI is S-nitrosylated in the affected neurons, which inhibits its enzymatic activity and thus allows protein misfolding to occur in ALS...
  45. ncbi Derlin-1-immunopositive inclusions in patients with Alzheimer's disease
    Yasuyuki Honjo
    Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Sakyoku, Koyoto, Japan
    Neuroreport 23:611-5. 2012
    ..Finally, they were involved in neurofibrillary tangles. These results suggest that derlin-1 may be associated with endoplasmic reticulum stress in neuronal cells in Alzheimer's disease...
  46. ncbi Protein disulfide isomerase immunopositive glial cytoplasmic inclusions in patients with multiple system atrophy
    Yasuyuki Honjo
    Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan
    Int J Neurosci 121:543-50. 2011
    ..Nitric-oxide-induced (NO-induced) S-nitrosylation of PDI inhibits its enzymatic activity, leading to the accumulation of polyubiquitinated proteins, and activates the unfolded protein response in neurodegenerative diseases...
  47. ncbi Cytokine receptor as a sensitizer for targeted cancer therapy
    Koji Kawakami
    Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Anticancer Drugs 13:693-9. 2002
    ..This unique approach comprising gene transfer of cytokine receptor chain and receptor-targeted cytotoxin administration represents a novel strategy for cancer therapy...
  48. ncbi Cytotoxic activity to acute myeloid leukemia cells by Antp-TPR hybrid peptide targeting Hsp90
    Tomohisa Horibe
    Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Yoshida Konoecho, Sakyoku, Kyoto 606 8501, Japan
    J Biosci Bioeng 114:96-103. 2012
    ..These results indicated that Antp-TPR hybrid peptide would provide potent and selective therapeutic options in the treatment of AML...
  49. ncbi Night-to-night variability of sleep latency significantly predicts the magnitude of subsequent change in sleep latency during placebo administration
    Atsushi Ogawa
    Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Yoshida konoe cho, Sakyo ku Kyoto, Japan
    Sleep Med 12:565-71. 2011
    ..To investigate the association between subjective sleep latency (sSL) fluctuation during the lead-in period and the placebo response in the subsequent double-blind period...
  50. ncbi The current status of umbilical cord blood collection in Japanese medical centers: survey of obstetricians
    Noriko Tada
    Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan
    Transfus Apher Sci 44:263-8. 2011
    ..The obstetricians involved in the UCB collection are generally willing to participate in the procedure under current circumstances at medical institutes...
  51. ncbi Molecular mechanism of cytotoxicity induced by Hsp90-targeted Antp-TPR hybrid peptide in glioblastoma cells
    Tomohisa Horibe
    Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan
    Mol Cancer 11:59. 2012
    ..abstract:..
  52. ncbi The cost of antiemetic therapy for chemotherapy-induced nausea and vomiting in patients receiving platinum-containing regimens in daily practice in Japan: a retrospective study
    Shota Hamada
    Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Yoshidakonoecho, Sakyo ku, Kyoto, Japan 606 8501
    Support Care Cancer 20:813-20. 2012
    ..The objective of this study was to estimate the cost of antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in daily practice in Japan...
  53. ncbi Clinical usefulness of pit patterns for detecting colonic lesions requiring surgical treatment
    Yasutoshi Kobayashi
    Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Yoshida Konoecho, Sakyoku, Kyoto, 606 8505, Japan
    Int J Colorectal Dis 26:1531-40. 2011
    ..We propose and evaluate a new clinical classification for pit patterns that uses endoscopy to assess lesion depth for determination of the appropriate therapeutic approach for early colorectal cancers and adenomas...
  54. ncbi Industry views of biosimilar development in Japan
    Hiroshi Horikawa
    Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan
    Health Policy 91:189-94. 2009
    ..To understand the issues around biosimilar development by pharmaceutical companies in Japan, which has emerged as an urgent issue in guaranteeing the availability of affordable biopharmaceuticals and a reduction in drug costs...
  55. ncbi Protein disulfide isomerase-immunopositive inclusions in patients with Alzheimer disease
    Yasuyuki Honjo
    Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Japan
    Brain Res 1349:90-6. 2010
    ..Consequently, the accumulation of misfolded proteins induces ER stress. The ER stress can cause apoptosis of neuronal cells. These results suggest that PDI could be a therapeutic target to prevent ER stress in neuronal cells in AD...
  56. ncbi Good Laboratory Practice (GLP) status of Asian countries and its implementation in non-clinical safety studies in pharmaceutical drug development
    Madoka Sasaki
    Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Sakyo ku, Kyoto, Japan
    J Toxicol Sci 34:493-500. 2009
    ..These findings will be beneficial to pharmaceutical companies planning GLP studies in Asian countries...
  57. ncbi Sample size calculations for controlling the distribution of false discovery proportion in microarray experiments
    Tomonori Oura
    Department of Biostatistics, Kyoto University School of Public Health, Yoshidakonoe cho, Sakyo ku, Kyoto 606 8501, Japan
    Biostatistics 10:694-705. 2009
    ..Gene clustering is proposed to identify gene blocks using historical data sets. The adequacy of the procedure is demonstrated using simulated data sets. An application to a clinical study for lymphoma is also provided...
  58. ncbi Oseltamivir Prescription and Regulatory Actions Vis-à-Vis Abnormal Behavior Risk in Japan: Drug Utilization Study Using a Nationwide Pharmacy Database
    Hisashi Urushihara
    Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan
    PLoS ONE 6:e28483. 2011
    ....
  59. ncbi Familiarity and prudence of the Japanese public with research into induced pluripotent stem cells, and their desire for its proper regulation
    Ryuma Shineha
    Graduate School of Biostudies, Kyoto University, Kyoto, Japan
    Stem Cell Rev 6:1-7. 2010
    ..It will be necessary to discuss an internationally consistent regulatory system and effective mechanisms for information flow...
  60. ncbi Development safety update reports and proposals for effective and efficient risk communication
    Hisashi Urushihara
    Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan
    Drug Saf 33:341-52. 2010
    ..To this end, we believe that the international regulatory community should undertake the new initiative for integrated periodic reporting immediately...
  61. ncbi Critical issues for effective collaboration between academia and industry in the field of regenerative medicine in Japan
    Mina Tsubouchi
    Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Yoshidakonoecho, Sakyoku, Kyoto 606 8501, Japan
    Regen Med 3:497-504. 2008
    ..To identify which factors are important barriers to effective collaboration between Japanese academia and industry in the field of regenerative medicine...
  62. ncbi Interleukin 4 receptor-directed cytotoxin therapy for human head and neck squamous cell carcinoma in animal models
    Scott E Strome
    Department of Otolaryngology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 8:281-6. 2002
    ..These data demonstrate that IL-4 (38-37)-PE38KDEL is effective in mediating significant antitumor effects in SCCHN and may represent an attractive therapeutic option for patients with advanced cancers of the upper aerodigestive tract...
  63. ncbi Adenoviral vector-mediated gene transfer of IL-13Ralpha2 chain followed by IL-13 cytotoxin treatment offers potent targeted therapy for cytotoxin-resistant cancers
    Makoto Saito
    Laboratory of Molecular Biology of Infectious Agents, Department of Molecular Microbiology and Immunology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan
    Int J Cancer 116:1-8. 2005
    ....
  64. ncbi MIP-T3 associates with IL-13Ralpha1 and suppresses STAT6 activation in response to IL-13 stimulation
    Yamei Niu
    Division of Molecular Pharmacology of Infectious Agents, Graduate School of Biomedical Science, Nagasaki University, Nagasaki 852 8521, Japan
    FEBS Lett 550:139-43. 2003
    ..These results suggest that MIP-T3 is a novel inhibitor of IL-13 signaling and may be a useful molecule in ameliorating various conditions in which IL-13 plays a central role...
  65. ncbi Quantitative measurement of neurological deficit after mild (30 min) transient middle cerebral artery occlusion in rats
    Kouji Wakayama
    Department of Advanced Clinical Science and Therapeutics, Graduate School of Medicine, The University of Tokyo, Japan
    Brain Res 1130:181-7. 2007
    ..Thus, the Montoya staircase test and methamphetamine-induced rotation are useful to evaluate neurological deficit in the chronic stage of subcortical infarction induced by 30-min tMCAo...